Peer-reviewed veterinary case report
Heat shock protein levels in dog bone cancer and survival
By Romanucci, Mariarita et al.·Published in Cell stress & chaperones·2012·Department of Comparative Biomedical Sciences, Italy·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Heat shock protein expression in canine osteosarcoma.
- Species:
- dog
Plain-English summary
A study looked at 18 dogs with osteosarcoma, a type of bone cancer, to see how certain proteins (heat shock proteins) might relate to their prognosis. They found that dogs with high levels of one protein, Hsp72, had a worse outlook, while those with little to no Hsp72 had a better chance of survival. The researchers suggest that targeting Hsp90, which was found in all tumor cases, could be a potential treatment option for dogs with this cancer. This information could help veterinarians better understand and treat osteosarcoma in dogs.
People also search for: dog osteosarcoma prognosis · heat shock proteins in dogs · treatment for dog bone cancer
Abstract
Abnormal levels of heat shock proteins have been observed in a number of human neoplasms and demonstrate prognostic, predictive and therapeutic implications. Since osteosarcoma (OSA) in dogs provides an important model for the same disease in humans, the aim of this study was to evaluate the immunohistochemical expression of Hsp27, Hsp72, Hsp73 and Hsp90 in 18 samples of canine appendicular OSA, in relation to histological grade and overall survival (OS), in order to investigate their potential prognostic, predictive and/or therapeutic value. A semiquantitative method was used for the analysis of the results. Hsp27, Hsp73 and Hsp90 showed a variably intense, cytoplasmic and nuclear immunoreactivity that was not associated with histological type or grade. On the other hand, a high percentage of Hsp72 immunostaining was significantly associated with grade III (P < 0.01) and a lack of immunolabelling was significantly correlated to a longer OS (P = 0.006). Neoplastic emboli were occasionally positive for Hsp27, faintly immunoreactive for Hsp72 and intensely immunolabelled by Hsp73 and Hsp90. In conclusion, absence of Hsp72 immunosignal appears to be associated with a favourable prognosis whilst the widespread Hsp90 immunoreactivity detected in all tumour cases as well as in neoplastic emboli, suggests this protein could be targeted in the therapy of canine OSA, and likewise in its human counterpart.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/22015573/